



www.mvtpharma.com

## INDUSTRY

- Diagnostics/Theranostics

## STAGE

- Pre-A

## FINANCING

- Money raised: \$2.1M seed, \$5M in kind and \$12M non-dilutive funds (NIH, DOD)

## KEY FACTS

- Year founded: 2009
- US HQ: Tucson Arizona (USA)

## MARKET OPPURTUNITY

Evan Unger (founder of the company) developed the #1 selling ultrasound contrast agent (USCA) with 80% market share in the US. Their new improved USCA is near term revenue. Their theranostic product is treating vascular thrombosis, affecting over 1 million Americans. It is safe and efficient for patients with contra-indications to current therapy.

## TEAM



### Evan Unger, M.D., Interim CEO, Executive Chairman of the board

- >30 years of experience in the field of microbubble technology
- Investor on >120 issued patents
- Co-founder of four biotech companies. The first company developed 3 FDA approved products including world's #1 selling ultrasound contrast agent and yielded > 20 x ROI. His second company went public.



### Emmanuelle Meillet, Ph.D., CSO/COO

- Co-founder of two biotech companies.
- well versed in the technology and the science, managed >\$20M in non-diluting funds.



### Marty Rosenberg, M.D., CMO

- Has many FDA-approved drugs and over 30 years of expertise in trials and imaging agents.

# MICROVASCULAR THERAPEUTICS, INC

## DESCRIPTION

Microvascular Therapeutics is a clinical stage biopharma pioneering in ultrasound contrast agents and theranostics. The technology affords a true platform of products with applicability in vascular, oncological and neurodegenerative diseases.

## PRODUCT/TECHNOLOGY/IP

Platform technology based on lipid/gas microbubbles as contrast agent for diagnosis and theranostics.

## MAJOR MILESTONE

MVT-100:

- GMP batches manufactured on site in 2018
- Exclusive licensing for Phase Shift Microbubble technology in 2018
- IND approval for clinical trial (Phase I/II) regulated via the 505(B)(2) regulatory pathway in 2019-2020

MVT-101:

- pre-IDE meeting, regulation as device, \$4M DOD award for IND-enabling studies in myocardial infarction were finished in 2023



## PARTNERSHIP/TRACTION

They are addressing an unmet medical need for patients with acute DVT (Deep vein thrombosis). Available treatments provided are long, dangerous and costly. MVT-101 offer a safe, effective and rapid treatment of vascular thromboses. They are on track to file an IDE and start a pilot clinical study.

## EXIT

- Expect acquisition of entire company or a subsidiary (vascular thrombosis sub) by commercial partner likely after IDE filing or PMA filing for vascular thrombosis indication.
- More than 10x ROI is highly feasible on basis of only MVT-101. Other assets have additional upside potential.
- Expectation for a partnership for MVT-100 with commercial collaborator, which will distribute and market product.
- PMA filing (MVT-101) will occur in 3 years and NDA filing (MVT-100) will occur in 2-3 years.

## COMPETITIVE ADVANTAGE

Evan Unger (founder of the company) developed the #1 selling ultrasound contrast agent with 80% market share in the US. From there the company have developed a new improved ultrasound contrast agent which they are using a platform for theranostics. Their theranostic target is vascular thrombosis, affecting over 1 million Americans. Their product is novel, less invasive and applicable for patients with contra-indications to current therapy.